DNMT3A and essential thrombocythemia: Similarly, Luque Paz et al. observed that the most frequent mutations in patients with PV and ET were also TET2, ASXL1, IDH1/2, and DNMT3A. They observed that patients with additional mutations had evidence of progression at 3 years.